Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exact Sciences Corp EXAS

Healthcare Biotechnology
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test... see more

Recent & Breaking News (NDAQ:EXAS)

Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting

PR Newswire April 12, 2023

Exact Sciences schedules first quarter 2023 earnings call

PR Newswire April 10, 2023

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

PR Newswire February 23, 2023

Exact Sciences to participate in March investor conferences

PR Newswire February 22, 2023

Exact Sciences Announces Fourth Quarter 2022 Results

PR Newswire February 21, 2023

Exact Sciences Launches OncoExTra(TM) Cancer Therapy Selection Test in the U.S.

PR Newswire February 7, 2023

Exact Sciences schedules fourth quarter 2022 earnings call

PR Newswire February 1, 2023

Exact Sciences Announces Preliminary Fourth Quarter 2022 Results

PR Newswire January 8, 2023

Exact Sciences to participate in J.P. Morgan Healthcare Conference

PR Newswire January 3, 2023

Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test

PR Newswire December 20, 2022

Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

PR Newswire December 9, 2022

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

PR Newswire December 6, 2022

Exact Sciences Announces Third Quarter 2022 Results

PR Newswire November 3, 2022

Exact Sciences to participate in November investor conferences

PR Newswire November 1, 2022

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

PR Newswire October 24, 2022

Exact Sciences schedules third quarter 2022 earnings call

PR Newswire October 10, 2022

Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

PR Newswire September 10, 2022

Exact Sciences to participate in September investor conference

PR Newswire September 1, 2022

Exact Sciences Announces Second Quarter 2022 Results

PR Newswire August 2, 2022

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

PR Newswire August 2, 2022